US biotech firm donating 1.5 million doses of experimental coronavirus drug

TheHill | April 05, 2020

Gilead Sciences Inc., a U.S. biotechnology firm that develops and commercializes drugs, has rapidly expanded its supply of an experimental coronavirus drug and is prepared to donate 1.5 million doses of it to hospitals dealing with severely ill patients. Gilead CEO Daniel O'Day said in a statement Saturday that the 1.5 million doses of the drug, known as remdesivir, could be part of treatment courses for as many as 140,000 patients. He said the doses were available for "compassionate use, expanded access and clinical trials and will be donated for broader distribution following any potential future regulatory authorizations."He also noted that the drug would be offered free of charge to hospitals or physicians who apply for its emergency use. Remdesivir remains an experimental drug without regulatory approval.

Spotlight

SpectraMax® Paradigm® Detection Platform with TUNE cartridge, delivers 1 nm wavelength flexibility while showcasing the sensitivity of filter-based systems. Powered by our SoftMax® Pro 6 Software, your assays can be optimized in as little as half the time. Learn how by viewing our latest animation!


Other News
INDUSTRIAL IMPACT

Calyxt Announces Pricing of Offering Of Common Stock and Warrants and Updates Business and Risk Factor Disclosure

Cellectis Inc. | February 19, 2022

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants will have an exercise price of $0.0001 per share of Calyxt common stock and the common warrants will have an exercise price of $1.41 per share of Calyxt common stock. The pre-funded warrants will be immediately exercisable and remain exercisable until exercised, while the common warrants will be exercisable six months after the date of issuance and will have a term of five years from the date of exercisability. The aggregate public offering price for each share of common stock or each pre-funded warrant and, in each case, an accompanying common warrant was $1.41. All securities sold in the Offering were sold by Calyxt. In connection with the Offering, Calyxt disclosed certain preliminary estimated financial information as of December 31, 2021: Calyxt’s cash and cash equivalents was $13.7 million, restricted cash was $0.6 million, total current liabilities were $4.1 million, and financing lease obligations, including current portion, were $17.9 million. This preliminary financial information, which has not been audited, is based on information currently available to Calyxt and is subject to the completion of Calyxt’s year-end financial closing procedures. It is possible that Calyxt’s independent registered public accounting firm may identify items that require Calyxt to make adjustments to the preliminary estimates set forth above and those changes could be material. In connection with the Offering, Calyxt also provided an updated description of certain aspects of its business and updated the risk factor disclosure from Calyxt’s prior filings with the U.S. Securities and Exchange Commission. About Cellectis  Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR-T cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.   Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market and on Euronext Growth.   About Calyxt Calyxt is a plant-based synthetic biology company. The Company leverages its proprietary PlantSpring™ technology platform to engineer plant metabolism to produce innovative and high value plant-based chemistries for use in customers' materials and products. As plant-based solutions, the Company's synthetic biology products can be used in helping customers meet their sustainability targets and financial goals. Calyxt's diversified offerings are primarily delivered through its proprietary BioFactory™ production system.

Read More

MEDTECH

BIO-ISAC and New York Metro InfraGard Membership Alliance Announce Partnership

NY Metro InfraGard | April 28, 2022

The Bioeconomy Information Sharing and Analysis Center (BIO-ISAC) and New York Metro InfraGard Members Alliance® (NYM-IMA) today announced a partnership to address threats unique to the bioeconomy and enable coordination among stakeholders to facilitate a robust and secure industry. BIO-ISAC is a critical resource for cyber threat detection, prevention, protection, response, recovery and resilience in the bioeconomy. It helps spur the development and evaluation of defensive tools to address ongoing and emerging threats, and includes vulnerability identification and mitigation, and education and outreach, aimed at reducing risk to the nation's biosecurity infrastructure. BIO-ISAC partnering with NYM-IMA advances our efforts to strengthen our resilience from attacks on the public and private bioeconomy infrastructure. We look forward to developing our collaboration to further enhance, maintain and implement best practices and standards to improve global digital biosecurity." Nina Alli, board member of BIO-ISAC. The bioeconomy is defined as economic activity driven by research and innovation in the life sciences and biotechnology and enabled by technological advances in engineering and in computing and information sciences. A National Academies of Sciences, Engineering, and Medicine report published in 2020 values the bioeconomy at more than 5 percent of U.S. gross domestic product, or more than $950 billion.* The digitization of life sciences has resulted in the emergence of a complex ecosystem plagued with cybersecurity challenges. We are privileged to collaborate with the BIO-ISAC, a team of exceptionally talented technologists. We support their efforts and share their commitment to safeguarding the cybersecurity of the bioeconomy. To protect our bioeconomy adequately, we must constantly assess the current threat landscape and our response capabilities. This collaboration broadens our aperture, and we believe it will have a significant impact." Jennifer Gold, president, NY Metro InfraGard. The bioeconomy spans multiple U.S. Critical Infrastructure sectors, including Health Care and Public Health, Critical Manufacturing, Food and Agriculture, Chemical, Energy, Government Facilities, Information Technology, Water and Wastewater, and the Defense Industrial Base Sectors. BIO-ISAC members are bioeconomy-connected industry leaders, organizations, and academic institutions connected to Biomanufacturing, BioPharma, BioProducts (synthetic bio), software and hardware vendors, national security, and agriculture. BIO-ISAC also acts as the convening place for trusted international partners to collaborate on digital biosecurity and biological supply chain security issues. InfraGard is a partnership between the Federal Bureau of Investigation (FBI) and members of the private sector for the protection of U.S. Critical Infrastructure. Through seamless collaboration, InfraGard connects owners and operators within critical infrastructure to the FBI, to provide education, information sharing, networking, and workshops on emerging technologies and threats. InfraGard's membership includes business executives, entrepreneurs, lawyers, security personnel, military and government officials, IT professionals, academia and state and local law enforcement—all dedicated to contributing industry-specific insight and advancing national security.

Read More

INDUSTRIAL IMPACT

MindMed Announces Transitions to Management Team

Mind Medicine (MindMed) Inc. | December 30, 2021

Mind Medicine Inc. a leading biotech company developing psychedelic-inspired therapies, announced that its Chief Technology Officer, Bradford Cross, has transitioned from his role. "On behalf of the Board of Directors and Executive team, I would like to thank Bradford for his contributions to the Company and wish him all the best in his future endeavors. We remain dedicated to advancing our pipeline and ongoing digital therapeutics platform forward under the leadership of MindMed Chief Medical Officer, Dr. Daniel Karlin. We enter 2022 well positioned both financially and strategically to continue on our mission to transform mental health treatment." Robert Barrow, Chief Executive Officer and Director of MindMed Additionally, Don Gehlert, PhD will be transitioning from his role as CSO and will continue as a Senior Scientific Advisor. Mr. Barrow added "Don has been and will continue to be an integral part of our organization. While this represents a change in his title, our entire team will continue to work closely with Don and benefit from his incredible breadth of experience in developing innovative CNS therapeutics." About MindMed MindMed is a clinical-stage biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Read More

INDUSTRIAL IMPACT

IFF to Acquire Health Wright Products

IFF | February 17, 2022

IFF announced that it has entered into an agreement to acquire Health Wright Products, LLC (HWP), a leader in formulation and capsule manufacturing for the dietary supplement industry. Founded in 1995, HWP is located in Clackamas, Oregon, USA, and is a privately-owned and long-time business partner of IFF’s Health & Biosciences probiotics business. HWP is a global leader in the consumer Health and Nutrition industries, providing the highest-quality nutritional supplements. Using state-of-the-art processes and equipment, HWP manufactures custom formulations, and delivers encapsulation and packaging to meet the industries’ more exacting requirements for probiotic products. With over 165,000 ft2 (15,328 m2) of manufacturing space, the company generated approximately $100 million in annual revenue in 2021 and employed over 225 people who will continue with the company after the sale. The acquisition will bring formulation and finished format capabilities to IFF’s Health & Biosciences probiotics, natural extracts and botanicals businesses, allowing for innovation in custom formulation and combination products through joint capabilities. “Today’s announcement is driven by our commitment to enhance long-term value to our partners and customers. Producing thousands of unique and complex formulations for the industry’s most trusted brands, Health Wright Products formulation and finished format abilities will allow us to develop new and customized solutions and formats for a broad base of customers,” Simon Herriott, President, IFF’s Health & Biosciences division “We look forward to joining IFF’s Health & Biosciences division. Health Wright Products best-in-class quality manufacturing and formulation capabilities, combined with the strong biotech innovation pipeline of IFF’s Health & Biosciences, is an exciting proposition for our customers and employees,” said Mark Wright, President, Health Wright Products. The sale is expected to close in the first quarter of 2022, subject to customary closing conditions, and regulatory clearances. Financial terms of the deal have not been disclosed. About Health Wright Products, LLC. At Health Wright Products, a contract manufacture of dietary supplements, Quality, Service and Value have been the driving principles in our commitment to exceeding customers’ expectations. We partner with brands committed to the same driving principles for themselves and their customers. As a global industry leader, we leverage innovation, technology, experience and capacity to offer better solutions to current and emerging products. Providing better health by Encapsulating Excellence. About IFF’s Health & Biosciences division Inspired by nature and distinguished by its world-class bioscience and microbiome capabilities, IFF’s Health & Biosciences division is a leading innovation partner for customers across a broad range of consumer product, industrial and agricultural sectors. IFF’s Health & Biosciences division works closely with our customers to enhance products – and their processes – to deliver safer, healthier and more sustainable solutions. Welcome to IFF At IFF an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves.

Read More

Spotlight

SpectraMax® Paradigm® Detection Platform with TUNE cartridge, delivers 1 nm wavelength flexibility while showcasing the sensitivity of filter-based systems. Powered by our SoftMax® Pro 6 Software, your assays can be optimized in as little as half the time. Learn how by viewing our latest animation!

Resources